A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 10, Issue 6, 2004, Pages 751-757

  Bonner, Gregory F ^a,b   Fakhri, Alifiya ^a   Vennamanemi, Sridhar R ^a  

^a DEPARTMENT OF COLORECTAL SURGERY   (United States)

^b NONE   (United States)

Author keywords

Crohn's disease; Exacerbation; Inflammatory bowel disease; Nonsteroidal anti inflammatory drugs; Ulcerative colitis

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL MASS; ABDOMINAL PAIN; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; ULCERATIVE COLITIS; WELLBEING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; CROHN DISEASE; DRUGS, NON-PRESCRIPTION; FEMALE; FLORIDA; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT ACCEPTANCE OF HEALTH CARE; PROSPECTIVE STUDIES; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 9144237037     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200411000-00009     Document Type: Article

References (29)

1. Kaufmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med. 1987;107:513-516.
2. Rampton DS, Sladen GE. Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs. Postgrad Med J. 1981; 57:297-299.
3. Walt RP, Hawkey CJ, Langman MJS. Colitis associated with non-steroidal anti-inflammatory drugs. BMJ. 1984;288:238.
4. Rampton DS, McNeil NI, Sarner M. Analgesic ingestion and other factors preceding relapse in ulcerative colitis. Gut. 1983;24:187-189.
5. Pearson DJ, Stones NH, Bentley SJ. Proctocolitis induced by salicylates and associated with asthma and recurrent nasal polyps. BMJ 1983;287: 1675.
6. Rutherford D, Stockdill G, Hamer-Hodges DW, et al. Proctocolitis induced by salicylate. BMJ. 1984;288:794.
7. Chakraborty TK, Bhatia D, Heading RC, et al. Salicylate induced exacerbation of ulcerative colitis. Gut. 1987;28:613-615.
8. Shanahan F, Targan S. Sulfasalazine and salicylate-induced exacerbation of ulcerative colitis. N Engl J Med. 1987;317:455.
9. Gibson GF, Whitacre EB, Ricotti CA. Colitis induced by nonsteroidal anti-inflammatory drugs. Arch Intern Med. 1992;152:625-632.
10. Evans JMM, McMahon AD, Murray FE, et al. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut. 1997;40:619-622.
11. Felder JB, Korelitz BI. The influence of non-steroidal anti-inflammatory drugs on inflammatory bowel disease. Am J Gastroenterol. 1992;87:316.
12. Bonner GF, Walczak M, Kitchen L, et al. Tolerance of nonsteroidal anti-inflammatory drugs in patients with inflammatory bowel disease. Am J Gastroenterol. 2000;95:1946-1948.
13. Myren J, Bouchier IAD, Watkinson G, et al. The O.M.G.E. multinational inflammatory bowel disease survey 1976-1982. Scand J Gastroenterol. 1984;95:1-27.
14. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330: 1841-1845.
15. Zeger SL, Liang K-Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-130.
16. Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol. 1998;93:2037-2045.
17. Talley NJ, Evans JM, Fleming KC, et al. Nonsteroidal anti-inflammatory drugs and dyspepsia in the elderly. Dig Dis Sci. 1995;40:1345-1350.
18. Bonner GF. Exacerbation of inflammatory bowel disease associated with use of celecoxib. Am J Gastroenterol. 2001;94:1306-1308.
19. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs. N Engl J Med. 1999;340:1888-1899.
20. Reinisch W, Miehsler WP, Dejaco C, et al. Treatment of peripheral arthropathy in IBD with rofecoxib, a selective COX-2 inhibitor. Gastroenterology. 2001;120:A277.
21. Mahadevan U, Loftus EV, Tremaine WJ, et al. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol. 2001;97:910-914.
22. Felder JB, Korelitz BI, Rajapakse R, et al. Effects of nonsteroidal anti-inflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol. 2000;95:1949-1954.
23. Dominitz JA, Koepsell TD, Boyko EJ. Association between analgesic use and inflammatory bowel disease (IBD) flares: a retrospective cohort study. Gastroenterology. 2000;118:A581.
24. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology. 1997;112:1000-1016.
25. Blikslager AT, Zimmel DN, Young KM, et al. Recovery of ischaemic porcine ileum: evidence for a contributory role of COX-1 and COX-2. Gut. 2002;50:615-623.
26. Singer II, Kawka DW, Schloemann S, et al. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology. 1998;115:297-306.
27. Bonner GF. Exacerbation of inflammatory bowel disease associated with use of celecoxib. Am J Gastroenterol. 2001;94:1306-1308.
28. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine. 1976;55:401-412.
29. Bonner GF, Vennamaneni S. Use of nonsteroidal anti-inflammatory drugs in outpatients with inflammatory bowel disease. Gastroenterology. 2001; 120:A-269.